Similar articles for PMID: 26469164

Year	Number of Results
1999	1
2001	2
2002	1
2003	4
2005	1
2006	2
2007	3
2008	8
2009	2
2010	4
2011	7
2012	8
2013	6
2014	5
2015	9
2016	6
2017	7
2018	1
2019	2
2024	0

1

[Administration Order of FEC-DOC in Breast Cancer Adjuvant Chemotherapy Has an Effect on Toxicity].

Miyaki T, Tsujimura H, Nakamura R, Okubo Y, Kumagai K, Yamamoto N. Miyaki T, et al. Gan To Kagaku Ryoho. 2015 Sep;42(9):1081-5. Gan To Kagaku Ryoho. 2015. PMID: 26469164 Japanese.

2

[Feasibility of FEC 100 followed by DOC 100 as adjuvant chemotherapy for breast cancer].

Abe H, Umeda T, Tanaka M, Kawai Y, Mori T, Cho H, Kubota Y, Mekata E, Kurumi Y, Tani T. Abe H, et al. Gan To Kagaku Ryoho. 2010 Aug;37(8):1483-7. Gan To Kagaku Ryoho. 2010. PMID: 20716872 Clinical Trial. Japanese.

3

Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer.

Abe H, Mori T, Kawai Y, Cho H, Kubota Y, Umeda T, Kurumi Y, Tani T. Abe H, et al. Int J Clin Oncol. 2013 Jun;18(3):487-91. doi: 10.1007/s10147-012-0407-7. Epub 2012 Apr 7. Int J Clin Oncol. 2013. PMID: 22484576

4

Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).

Saloustros E, Malamos N, Boukovinas I, Kakolyris S, Kouroussis C, Athanasiadis A, Ziras N, Kentepozidis N, Makrantonakis P, Polyzos A, Christophyllakis C, Georgoulias V, Mavroudis D. Saloustros E, et al. Breast Cancer Res Treat. 2014 Dec;148(3):591-7. doi: 10.1007/s10549-014-3202-5. Epub 2014 Nov 16. Breast Cancer Res Treat. 2014. PMID: 25399229 Clinical Trial.

5

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.

Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Soulié P, Eichler F, Viens P, Monnier A, Vindevoghel A, Campone M, Goudier MJ, Bonneterre J, Ferrero JM, Martin AL, Genève J, Asselain B. Roché H, et al. J Clin Oncol. 2006 Dec 20;24(36):5664-71. doi: 10.1200/JCO.2006.07.3916. Epub 2006 Nov 20. J Clin Oncol. 2006. PMID: 17116941 Clinical Trial.

6

Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer.

Puhalla S, Mrozek E, Young D, Ottman S, McVey A, Kendra K, Merriman NJ, Knapp M, Patel T, Thompson ME, Maher JF, Moore TD, Shapiro CL. Puhalla S, et al. J Clin Oncol. 2008 Apr 1;26(10):1691-7. doi: 10.1200/JCO.2007.14.3941. Epub 2008 Mar 3. J Clin Oncol. 2008. PMID: 18316792 Clinical Trial.

7

Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence.

Wildiers H, Dirix L, Neven P, Prové A, Clement P, Squifflet P, Amant F, Skacel T, Paridaens R. Wildiers H, et al. Breast Cancer Res Treat. 2009 Mar;114(1):103-12. doi: 10.1007/s10549-008-9970-z. Epub 2008 Mar 16. Breast Cancer Res Treat. 2009. PMID: 18344024 Clinical Trial.

8

Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients.

Sanna G, Pestrin M, Zafarana E, Biagioni C, Cavaciocchi D, Turner N, Di Leo A, Biganzoli L. Sanna G, et al. Breast. 2013 Oct;22(5):926-32. doi: 10.1016/j.breast.2013.04.019. Epub 2013 May 22. Breast. 2013. PMID: 23707082

9

Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.

Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals J, Tres A, Marty M, Coleman RE, Tubiana-Mathieu N, den Boer MO, Wardley A, Kilburn LS, Cooper D, Thomas MW, Reise JA, Wilkinson K, Hupperets P. Coombes RC, et al. J Clin Oncol. 2011 Aug 20;29(24):3247-54. doi: 10.1200/JCO.2010.32.7254. Epub 2011 Jul 18. J Clin Oncol. 2011. PMID: 21768453 Clinical Trial.

10

Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study.

Cardoso F, Ferreira Filho AF, Crown J, Dolci S, Paesmans M, Riva A, Di Leo A, Piccart MJ. Cardoso F, et al. Anticancer Res. 2001 Jan-Feb;21(1B):789-95. Anticancer Res. 2001. PMID: 11299845 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

69 results

Results by year